When should amoxicillin versus azithromycin be used for acute bacterial sinusitis or community‑acquired lower respiratory infection?

Amoxicillin or Amoxicillin-Clavulanate Should Be Your First-Line Choice for Sinusitis and Respiratory Infections—Not Azithromycin

For acute bacterial sinusitis and community-acquired respiratory infections, use amoxicillin or amoxicillin-clavulanate as first-line therapy; reserve azithromycin only for penicillin-allergic patients. This recommendation is based on superior coverage of the primary pathogens (Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis), established efficacy, lower cost, and narrower microbiologic spectrum that reduces resistance pressure 1, 2, 3, 4, 5.

The Decision Algorithm

For Acute Bacterial Sinusitis:

Step 1: Confirm bacterial infection (not viral rhinosinusitis)

• Symptoms persisting ≥10 days without improvement, OR
• Severe symptoms (fever ≥38.3°C, purulent discharge, facial pain) for ≥3 consecutive days, OR
• "Double worsening" (initial improvement followed by worsening) 3, 4

Step 2: Choose your antibiotic based on risk factors

Low-risk patients (no recent antibiotics, age ≥2 years, no daycare exposure):

• Amoxicillin 45 mg/kg/day in 2 divided doses (adults: 500 mg TID or 875 mg BID) 2, 5
• Duration: 5-7 days is as effective as 10 days 5

High-risk patients (recent antibiotics within 30 days, age <2 years, daycare attendance, moderate-to-severe illness):

• High-dose amoxicillin-clavulanate 80-90 mg/kg/day (of amoxicillin component) in 2 divided doses 2, 5
• This covers β-lactamase-producing H. influenzae (10-42% prevalence) and M. catarrhalis (nearly 100% β-lactamase positive) 2

Penicillin allergy:

• Doxycycline or respiratory fluoroquinolone (levofloxacin, moxifloxacin) 4, 5
• Not azithromycin as first choice due to inferior pneumococcal coverage

For Community-Acquired Pneumonia (Outpatient):

Previously healthy, no recent antibiotics:

• Amoxicillin 1 g TID (high-dose to overcome pneumococcal resistance) 6
• Alternative: Macrolide (azithromycin, clarithromycin) for atypical coverage 6

Comorbidities or recent antibiotic use:

• Amoxicillin-clavulanate PLUS macrolide, OR
• Respiratory fluoroquinolone alone 6

For Acute Exacerbations of Chronic Bronchitis:

Anthonisen criteria (≥2 of 3: increased dyspnea, sputum volume, sputum purulence):

• Amoxicillin-clavulanate preferred over amoxicillin alone 1
• Azithromycin 500 mg daily × 3 days is FDA-approved and equivalent in efficacy 7, 8

Why Azithromycin Is NOT First-Line

The evidence is clear that azithromycin should be reserved for specific situations, not routine use:

1. Inferior pneumococcal coverage: 10-15% of S. pneumoniae are penicillin-nonsusceptible, but macrolide resistance is even higher and increasing 2. Amoxicillin at high doses overcomes most pneumococcal resistance; azithromycin does not.

2. Guidelines consistently recommend amoxicillin first: The 2013 Pediatrics guideline 2, 2015 AAO-HNS guideline 5, 2016 ACP/CDC guideline 4, and 2007 AAO-HNS guideline 3 all specify amoxicillin or amoxicillin-clavulanate as first-line, with azithromycin relegated to penicillin allergy.

3. Resistance concerns: Widespread macrolide use drives resistance 6. The narrow spectrum of amoxicillin is actually an advantage for antimicrobial stewardship.

4. No superiority in outcomes: While azithromycin shows equivalent cure rates in some studies 9, 10, it offers no mortality or morbidity benefit over amoxicillin-based regimens, and guidelines prioritize the agent with better pathogen coverage 2, 4, 5.

When Azithromycin IS Appropriate

Legitimate indications:

• Documented penicillin allergy (though second/third-generation cephalosporins are now considered safe even with penicillin allergy 2)
• Atypical pathogen coverage in community-acquired pneumonia (Mycoplasma, Chlamydophila) when combined with a β-lactam 6
• Patient adherence concerns: Single-dose or 3-day regimens may improve compliance 7, 11, but this convenience does not outweigh the microbiologic disadvantages for routine use

FDA-approved azithromycin dosing 7:

• Acute bacterial sinusitis: 500 mg daily × 3 days
• Community-acquired pneumonia: 500 mg day 1, then 250 mg daily days 2-5
• Acute exacerbation COPD: 500 mg daily × 3 days

Common Pitfalls to Avoid

1. Don't use azithromycin "because it's easier": The 3-day course is appealing, but amoxicillin 5-7 days is equally short and more effective 5.

2. Don't assume all sinusitis needs antibiotics: Viral rhinosinusitis (<10 days, not worsening) requires only symptomatic treatment 3, 4. Watchful waiting for 7 days is appropriate for mild acute bacterial sinusitis 3, 5.

3. Don't underdose amoxicillin: Standard dosing (500 mg TID) may be insufficient in high-resistance areas. Use 875 mg TID or 1 g TID for pneumonia 6, 5.

4. Don't forget local resistance patterns: If your community has >10% penicillin-nonsusceptible pneumococcus, start with high-dose amoxicillin (80-90 mg/kg/day) or amoxicillin-clavulanate 2.

5. Don't continue antibiotics beyond 5-7 days for sinusitis: Evidence supports shorter courses with equal efficacy and fewer adverse effects 5, 12.

The Bottom Line on Adverse Effects

Amoxicillin-clavulanate causes more diarrhea (32%) than azithromycin (17%) 7, 10, but this is manageable and does not justify using an inferior antibiotic. The overall treatment-related adverse event rate for azithromycin is still 14-31% 7, 9, primarily gastrointestinal. The slightly better tolerability of azithromycin does not outweigh its inferior pathogen coverage for first-line empiric therapy 4, 5.